8-K: Sera Prognostics Reports First Quarter 2025 Financial Results, Revenue Rises to $38,000

Sera Prognostics announces its first quarter 2025 financial results, highlighting a revenue increase to $38,000 and ongoing engagement with payors for its PreTRM test.

Summary

• Sera Prognostics reported its first quarter 2025 financial results on May 7, 2025.
• Revenue for the quarter was $38,000, compared to no revenue in the same period of 2024.
• Total operating expenses were $9.3 million, slightly up from $9.1 million in the first quarter of 2024.
• Research and development expenses decreased by approximately 9% to $3.3 million, primarily due to lower clinical study costs related to the PRIME study.
• Selling, general, and administrative expenses increased to $5.9 million from $5.4 million in the prior-year period.
• The net loss for the quarter was $8.2 million, compared to $8.1 million for the prior-year quarter.
• As of March 31, 2025, the company had approximately $114.2 million in cash, cash equivalents, and available-for-sale securities.
• The company is actively engaging with payors and plan administrators following the release of the PRIME study results.
• Sera is pursuing Medicaid opportunities, representing approximately half of the market for the PreTRM test, and is in discussions with several Medicaid plans across three states for implementation pilots.
• Jeff Elliott was appointed to the Board of Directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there is revenue growth, a decrease in R&D expenses, and a strong cash position. The company is also actively engaging with payors and expanding its market reach.

Positives

• Revenue increased to $38,000 in the first quarter of 2025 compared to nil in the same period of 2024.
• Research and development expenses decreased by approximately 9% due to lower clinical study costs.
• The company has a strong cash position with approximately $114.2 million in cash, cash equivalents, and available-for-sale securities.
• The company is actively engaging with payors and plan administrators following positive PRIME study results.
• Sera is pursuing Medicaid opportunities, which represent approximately half of the market opportunity for the PreTRM Test.
• Jeff Elliott was appointed to the Board of Directors.

Negatives

• The company reported a net loss of $8.2 million for the quarter.
• Total operating expenses were $9.3 million, slightly up from $9.1 million in the first quarter of 2024.
• Selling, general, and administrative expenses increased to $5.9 million from $5.4 million in the prior-year period.

Risks

• The company has a history of net losses and may need to raise more capital in the future.
• Revenues are substantially dependent on the PreTRM Test.
• Broad scientific and market acceptance of the PreTRM Test is necessary for continued growth.
• The company relies on a concentrated number of material customers.
• Changes in FDA regulation of laboratory-developed tests could impact the company.

Future Outlook

The company anticipates that Medicaid providers will see the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test.

Management Comments

• Zhenya Lindgardt, President and CEO of Sera Prognostics, stated that the company is leveraging the results of the PRIME pivotal study by engaging with key plan providers in focused geographic regions hard hit by premature birth.
• Zhenya Lindgardt anticipates that Medicaid providers in those areas will see the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test.

Industry Context

Sera Prognostics operates in the health diagnostics industry, specifically focusing on improving maternal and neonatal health through innovative pregnancy biomarker information. The company's PreTRM Test addresses the significant issue of preterm birth, which has substantial healthcare costs and long-term medical complications.

Comparison to Industry Standards

• Exact comparisons to industry standards are difficult without detailed competitor data, but companies like PerkinElmer and Natera also offer prenatal and neonatal screening tests.
• Sera's focus on preterm birth risk prediction with the PreTRM test differentiates it from broader screening approaches.
• The $25 billion annual healthcare costs associated with prematurity in the US, as estimated for 2016, highlight the significant market opportunity Sera is targeting.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and strategic initiatives will impact shareholder value.
• Patients: The PreTRM Test aims to improve outcomes for mothers and newborns.
• Payors: The company is actively engaging with payors to demonstrate the cost-effectiveness of the PreTRM Test.

Next Steps

• Sera plans to meet with attendees at the upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm.

Key Dates

Keywords

PreTRM Test, Sera Prognostics, preterm birth, financial results, maternal health, neonatal health, biomarker, Medicaid, revenue, PRIME study